Browse drugs

…y receptor OX40. Here, we investigate a treatment strategy with ABBV-368 combined with the investigational toll-like receptor 9 agonist …

…systemic palliative chemotherapy with NALIRIFOX, mFOLFIRINOX or Gem/NabP between January 2021 and July 2024. Key eligibility criteria re…

…the efficacy and safety of two cycles of induction therapy with bevacizumab and paclitaxel followed by atezolizumab and nab-paclitaxel comp…

…ypically delivered 5 days a week over 7 weeks concurrently with cisplatin, a regimen established through multiple randomised trials, demo…

…ducted, no agents have received approval, with the exception of valrubicin, largely attributed to factors such as the varied prior BCG exp…

…as ‘related,’ ‘most possibly related,’ or ‘possibly related’ to SSGJ-707 or tislelizumab.Abstract 1328 Figure 1Waterfall plots for SSGJ-…

…g DNV3 (anti-LAG-3), toripalimab (anti-PD-1), and chemotherapy (nab-paclitaxel/cisplatin) in 27 Asian patients with unresectable/metastatic me…

… for Gem/NabP. Recorded grade ≥3 toxicities appeared lower with NALIRIFOX, although cross-regimen safety comparisons were limited by retr…

…ng serplulimab with a taxane (paclitaxel or nab-paclitaxel) and carboplatin in patients with resectable stage II-IIIA sq-NSCLC.Methods This…

…patient in sitravatinib+tislelizumab arm; 13 (6.8%) patients in docetaxel arm) (figure 1). One patient randomised to sitravatinib+tisleli…

…umab (360 mg intravenously every 3 weeks) and cohort B received hydroxychloroquine (600 mg orally two times a day). The primary endpoint was safet…

…demonstrated durable antitumor response and was well tolerated. BMS-813160 combination regimens were tolerable in other cohorts, but clini…